Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results first posted: Jul 2, 2026
    • Primary endpoint revised
    • Enrollment target: estimated 26 to confirmed 28
    • Secondary endpoints: 1 to 2
    v13
  2. Trial status: Active, Not Recruiting to Completed
    • Primary and study completion dates: May 2009
    • Study arms: 0 to 1
    v12
  3. Lead sponsor: Case Comprehensive Cancer Center to The Cleveland Clinic
    • Collaborators expanded, about 4 words
    v11
  4. 2 versions Re-verified since Jul 23, 2008, no change to tracked fieldsv9-v10
  5. Interventions: antiangiogenesis therapy (Procedure), lenalidomide (Drug) to lenalidomide (Drug)v8
Show 6 earlier versionsHide 6 earlier versions
  1. Re-verified, no change to tracked fieldsv7
  2. Interventions: anti-cytokine therapy (Procedure), antiangiogenesis therapy (Procedure), biological therapy (Procedure), growth factor antagonist therapy… to antiangiogenesis therapy (Procedure), lenalidomide (Drug)v6
  3. Study Status, Eligibilityv5
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  5. Re-verified, no change to tracked fieldsv3
  6. Eligibility criteria shortened, about 5 words
    • Study description expanded, about 2 words
    • Study title expanded, about 2 words
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.
Trial Details
NCT Number NCT00403169
Lead Sponsor The Cleveland Clinic
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Kidney Cancer
Related terms Carcinoma, Renal Cell, Kidney Neoplasms
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov